Company profile: Immunai
1.1 - Company Overview
Company description
- Provider of immunology mapping and reprogramming solutions leveraging machine learning and software engineering, including AMICA—a comprehensive immune cell knowledge base integrating clinico-genomic data; single-cell analysis and functional genomics; and drug discovery and development support from target discovery and validation through compound validation and clinical trial optimization, with biopharma and academic partnerships contributing data back to AMICA.
Products and services
- AMICA: A platform-grade immune cell knowledge base integrating clinico-genomic data to enable therapeutic discovery and development, enriched by collaboration-derived improvements contributed back for further insights
- Single-cell analysis: A custom-engineered machine-learning pipeline providing detailed cell annotations, differential expression analysis, and gene regulatory network inference using machine learning
- Drug discovery & development: A translational-grade partnership service supporting target discovery, validation, compound validation, and clinical trial optimization throughout drug development stages
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Immunai
eClinical Solutions
HQ: United States
Website
- Description: Provider of a data intelligence hub that transforms clinical data integration, aggregation, and analytics, leveraging clinical trial expertise and platforms including Rave Clinical Cloud and the elluminate Clinical Data Cloud; offerings include Mapper, Data Central, Clinical Analytics, Risk-Based Quality Management, and eIQ Review to accelerate clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eClinical Solutions company profile →
Adimab
HQ: United States
Website
- Description: Provider of an antibody discovery and optimization platform developing full-length human Immunoglobulin Gs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adimab company profile →
H1
HQ: United States
Website
- Description: Provider of a health data platform supporting end-to-end therapeutic development for medical companies and healthcare systems. Offerings include Trial Landscape for principal investigator pools, site performance and patient diversity insights; GenosAI for querying trial data; HCP Universe to discover and engage HCPs; Precise doctor directory data; and H1 Connect for global humanitarian missions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full H1 company profile →
Antidote
HQ: United Kingdom
Website
- Description: Provider of digital health solutions that accelerate and improve medical research by combining proprietary technologies, data, and well-established business models. Offerings include Enterprise Match, a SaaS tool for patient-friendly clinical trial search and matching; Precision Recruitment using data-driven insights; Patient Engagement solutions; and a Partner Network to drive patient engagement and provide research resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antidote company profile →
Octant
HQ: United States
Website
- Description: Provider of a cellular intelligence platform for studying protein misfolding in human cells and enabling high-throughput screening; multiplexed readouts to measure protein folding and trafficking across hundreds of mutations and conditions; and development of novel therapeutics guided by massive datasets in engineered human cells to improve health and treat disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Octant company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Immunai
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Immunai
2.2 - Growth funds investing in similar companies to Immunai
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Immunai
4.2 - Public trading comparable groups for Immunai
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →